TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05316246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin in Combination with Tislelizumab
Description: Brentuximab vedotin will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a dose of 1.8 mg/kg. Tislelizumab will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a fixed dose of 200 mg. The rationale of fixed dose of Tislelizumab is according to the drug description, which is based on previous I/II phase clinical trial results of Tislelizumab. The time interval between administration of tislelizumab and brentuximab vedotin should be not less than 2 hours, and thereafter, the dosing cycle of tislelizumab is synchronized with that of brentuximab vedotin.
Study: NCT06098209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.
Study: NCT06694233

Intervention type: OTHER
Intervention: Aspirin prescription on outpatient basis
Description: Improving aspirin prescription rates for candidate patients (moderate- and high-risk obstetric population)
Study: NCT06631144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spanish-language Caregiver-Enabled Care Program (CECP)
Description: CECP is a nonmedical digital population health intervention to support and engage family caregivers of persons with dementia. CECP consists of digital content, including health education videos and tutorials, that is delivered to caregivers on a dedicated tablet based on their specific needs. Caregivers are supported by a proactive human coach who provides support, access to resources, and performs risk mitigation measures as necessary. Alerts are shared with providers and/or care management teams via a data hub that makes it easy to track, manage and resolve alerts. CECP is delivered over a 6-month period via a dedicated tablet that is shipped to the caregiver's home at no cost to the caregiver or person with dementia. This study's CECP is in Spanish.
Study: NCT06709079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals)
Description: Preoperatively, patients with AR were given 2 tablets of Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals) to be taken after meals, once in the morning and once in the evening, for a period of 20 days.
Study: NCT06710080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
Description: Participants randomized to the treatment arm will receive Vascepa 1000mg twice a day for 6 months.
Study: NCT06220565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sensor and wearable device Graded Exercise
Description: The program plans to use rational mechanism to provide safe and targeted exercise interventions to patients at different stages of their lives through three aspects: education, motivation and feedback. Through real-time collection of knee function parameters, real-time feedback on the effect of exercise intervention, and tracking the changes in the functional status of patients' knee joints. On the basis of improving knee function, we further improve patients' compliance with exercise intervention.~Considering the community scenario, we plan to use sensors and wearable devices to realize the function of the knee joint on the basis of the existing technology. wearable devices to realize the digital assessment of knee function to reduce patient's time and cost and improve efficiency. At the same time, this digital assessment will provide a basis for decision-making for patient self-management.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Description: exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise
Study: NCT06098209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patient will receive propofol 0.3-4 mg/kg/h.
Study: NCT04574115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega Refractive Capsule with an FDA approved Intraocular Lens
Description: Omega refractive capsule in conjunction with an FDA approved Intraocular Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved Intraocular Lens
Description: FDA approved Intraocular Lens
Study: NCT05094752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proprioceptive stimulations
Description: Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulations
Description: Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
Study: NCT06710080

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study: NCT06715735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory-based health behaviour change intervention
Description: The online individual education sessions are related to MetS, CKD, healthy dietary and PA, displayed in the form of texts and pictures, and online instant conversations via WeChat. The online group music-paced brisk walking training includes a 5-minute warm-up, 30-minute music-paced brisk walking, and 5-minute stretching exercises to promote cool-down. The group discussion is related to current health status, recommended dietary regimens, and exercise and personal goals. The telephone follow-up after the group discussion is to reinforce the predetermined goals and the practice of healthy dietary and music-paced brisk walking, and to provide opportunities for answering any questions related to the practice of healthy dietary and music-paced brisk walking. All the education session contents are based on a well-structured health handbook. The self-music-paced brisk walking is required to be performed for 30 minutes/day, 5 days/week.
Study: NCT06706167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stainless steel crown
Description: Participants in this arm received a stainless steel crown for primary teeth restoration. The crowns were selected based on the clinical assessment of the patient's dental need.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stainless steel crown
Description: Participants in this arm received a stainless steel crown for primary teeth restoration. The crowns were selected based on the clinical assessment of the patient's dental need.
Study: NCT04873531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery.
Study: NCT05028231

Intervention type: PROCEDURE
Intervention: Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy
Description: Each patient will complete 2 cycles of neoadjuvant therapy. After evaluating the curative effect, decide whether to operate or not. Patients with and without surgery enter the survival follow-up period.
Study: NCT03602040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PISICC
Description: PISICC consists of:~1. Standard disease-specific information leaflet~2. Personalised lifestyle consideration form~3. 1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c).
Study: NCT05256472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: an oral, small molecule, TKI selective for VEGFRs 1, 2 and 3; 5mg bid orally
Study: NCT05208658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Classical Vision Therapy Treatment
Description: Do classical vision therapy treatment for improve vergence

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental: Classical Vision Therapy Treatment
Description: Do classical vision therapy treatment for improve vergence

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control: Eye Movement Therapy Treatment
Description: Do eye movement therapy treatment in order not to improve vergence
Study: NCT06706167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stainless steel crown
Description: Participants in this arm received a stainless steel crown for primary teeth restoration. The crowns were selected based on the clinical assessment of the patient's dental need.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crown
Description: Participants in this arm received a zirconia crown for primary teeth restoration. The crowns were selected to provide a more aesthetic and durable option compared to stainless steel.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zirconia crown
Description: Participants in this arm received a zirconia crown for primary teeth restoration. The crowns were selected to provide a more aesthetic and durable option compared to stainless steel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crown
Description: Participants in this arm received a zirconia crown for primary teeth restoration. The crowns were selected to provide a more aesthetic and durable option compared to stainless steel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioflx crown
Description: Participants in this arm received a Bioflx crown, which is a flexible, biocompatible material often used for pediatric crowns.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioflx crown
Description: Participants in this arm received a Bioflx crown, which is a flexible, biocompatible material often used for pediatric crowns.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioflx crown
Description: Participants in this arm received a Bioflx crown, which is a flexible, biocompatible material often used for pediatric crowns.
Study: NCT06715384

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polyp size measurement using autonomous AI measurement or AI-assisted human measurement with the CAM system
Description: The study of real-time polyp size measurement using the CAM system will be conducted in two phases. Phase I (pilot phase, n=24 polyps, about 27 patients) will be used to assess the feasibility of applying the CAM system in real-time in a clinical video in order to obtain pilot data on the relative accuracy of assessing polyp sizes using autonomous AI measurement and AI-assisted human measurement and to determine the relative accuracy of assessing polyp size in Phase II of the study ( Randomized Controlled Trial) to assess the sample size and reference standards for the CAM system. The sample size for the second phase of the randomized controlled trial (comparing AI-assisted human measurement to non-scaled device) will be based on pilot data in order to compare the relative accuracy of polyp size measurement with AI-assisted human measurement versus non-scaled device in clinical practice.
Study: NCT06718426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fertitonex capsule
Description: Fertitonex which contains L- carnitine L-tartarate 300 mg, L-arginine 241mg, vitamin B6 1.1 mg, vitamin B12 1.7 mcg, vitamin D3 2 mcg, vitamin E 6.5 mg, vitamin C 60 mg, selenium 28 mcg, zinc 7.5 mg, folic acid 300 mcg and CoQ 10 enzyme 7.5 mg in each capsule. The dose will be one capsule twice daily for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: placebo oral capsule. the dose is twice daily for 3 months
Study: NCT06716359

Intervention type: OTHER
Intervention: Observational study without intervention
Description: Observational study without intervention
Study: NCT06719401

Intervention type: OTHER
Group type: OTHER
Intervention: Foot Chest Compression
Description: Foot chest compression is an alternative cardiopulmonary resuscitation (CPR) technique where the rescuer uses one foot to perform compressions on the chest instead of their hands. The heel of the foot is placed on the lower half of the sternum, with the foot parallel to the sternum to ensure effective pressure. The opposite foot provides stability by being positioned beside the patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Foot Chest Compression
Description: Foot chest compression is an alternative cardiopulmonary resuscitation (CPR) technique where the rescuer uses one foot to perform compressions on the chest instead of their hands. The heel of the foot is placed on the lower half of the sternum, with the foot parallel to the sternum to ensure effective pressure. The opposite foot provides stability by being positioned beside the patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Hand Chest Compression
Description: Hand chest compression is the conventional method of performing chest compressions during CPR. It involves the use of both hands, with one hand placed over the other on the lower half of the sternum. The rescuer positions their body directly over the patient, using the weight of their upper body to deliver compressions of 50-60 mm depth at a rate of 100-120 compressions per minute. Proper technique includes full chest recoil between compressions, maintaining a straight arm posture, and avoiding pressure on the xiphoid process to minimize injury risks. This method adheres to the 2020 AHA guidelines for high-quality CPR.

Intervention type: OTHER
Group type: OTHER
Intervention: Hand Chest Compression
Description: Hand chest compression is the conventional method of performing chest compressions during CPR. It involves the use of both hands, with one hand placed over the other on the lower half of the sternum. The rescuer positions their body directly over the patient, using the weight of their upper body to deliver compressions of 50-60 mm depth at a rate of 100-120 compressions per minute. Proper technique includes full chest recoil between compressions, maintaining a straight arm posture, and avoiding pressure on the xiphoid process to minimize injury risks. This method adheres to the 2020 AHA guidelines for high-quality CPR.
Study: NCT06717984

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy, Mastectomy, Histopathology
Description: Biopsy:~This intervention involves the collection of breast tissue samples through a biopsy procedure. These samples are obtained from women undergoing investigation for unusual cell growth and are analyzed to detect potential abnormalities, including benign, in situ, or invasive cancerous changes.~Mastectomy:~This intervention refers to the surgical removal of breast tissue, typically performed to treat or prevent the spread of breast cancer. It may involve the removal of part or all of the breast and is considered in cases of invasive breast cancer or high-risk noninvasive breast cancer.~Histopathology:~This intervention focuses on the microscopic examination of breast tissue samples collected through biopsy or mastectomy. Histopathological analysis is conducted to assess cellular abnormalities, determine the presence of cancer, and classify the tissue as benign, in situ, or invasive, providing the basis for diagnosis and treatment decisions.
Study: NCT06718842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking free online supervised program
Description: this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)
Study: NCT06220565

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational Manual
Description: Educational Manual
Study: NCT06714864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (taurolidine and heparin) catheter lock solution
Description: for central venous catheter instillation use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Site specific standard of care
Study: NCT06710288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose: 800 mg/m2 intravenously (IV) Frequency: administered on Day 1, Day 8, and Day 15 of each cycle (every 4 weeks)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Dose: fixed dose of 1.2 mg subcutaneously (SC) Frequency: administered on Day 1 and Day 15 of each cycle starting at Cycle 2 (every 4 weeks) and when the last dose of M-CENK is administered, N-803 will be administered on Days 1 and 15 of the same cycle followed by 3 additional doses, 2 weeks apart (total of 5 N-803 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-CENK
Description: Dose: 0.15 to 0.75 × 109 cells per infusion intravenously (IV) Frequency: administered on Day 1 of each cycle as long as M-CENK cells are available.
Study: NCT06719206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital self-management program
Description: The program consists of commercially available technologies, e.g. applications including behavour change techniques for reducing sedentary behavior (SB) (i.e. self-monitorization of physical activity, reminders for breaking SB/doing physical activity, and providing feedback on physical activity/breaks from SB) and a webpage containing information and tips (provided in short videos and text) regarding how to reduce SB. The participants will be receive help with setting goals for reducing time spent in sedentary/being active and help with planning for what activities to do to replace time in sedentary. Participants will then have access to the webpage and download the application to their smartphones. Follow-up meetings with the physiotherapist (digital or physical) will be conducted after 2, 8 and 12 weeks after start of intervention.
Study: NCT06715111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: A study used a laser acupuncture device to deliver treatment to 27 participants in Group A. The device, was designed for high power, non-thermal treatment. The device had a Class IV- high power, non-thermal laser with a wave length of 808-905 and a 650 nm wavelength. It had an ergonomic handpiece, high efficiency aiming beam, and adjustable emission intensity range. The device also included two laser safety goggles, a touchscreen stylus, and a retractable banner. Participants were instructed to relax and accurately detect acupoints before application. The device was adjusted for safety and both participants and researchers wore laser goggles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional pelvic floor exercise
Description: The study involved participants from groups A and B who underwent conventional pelvic floor exercises for four weeks. The exercises targeted the pubococcygeus, sphincter ani, and urethral musculatures. Participants underwent a warm-up phase with 3-5 minutes of breathing and circulatory exercises, followed by 10 repetitions, 3-5 sets, a 3-5 minute warm-up, 30 minutes of exercises, and a cool-down in five minutes. The exercise program was repeated three times per week for four weeks. Participants were instructed to ensure bladder emptiness, relax, perform contractions and relaxations, squeeze pelvic floor musculatures around the anus and vagina, and maintain contact with the plinth. The cool-down phase involved supervised training for 3-5 minutes of breathing and circulatory exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional pelvic floor exercise
Description: The study involved participants from groups A and B who underwent conventional pelvic floor exercises for four weeks. The exercises targeted the pubococcygeus, sphincter ani, and urethral musculatures. Participants underwent a warm-up phase with 3-5 minutes of breathing and circulatory exercises, followed by 10 repetitions, 3-5 sets, a 3-5 minute warm-up, 30 minutes of exercises, and a cool-down in five minutes. The exercise program was repeated three times per week for four weeks. Participants were instructed to ensure bladder emptiness, relax, perform contractions and relaxations, squeeze pelvic floor musculatures around the anus and vagina, and maintain contact with the plinth. The cool-down phase involved supervised training for 3-5 minutes of breathing and circulatory exercises.
Study: NCT06717724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Periarticular Procaine Injection (PAPI)
Description: Participants will receive periarticular 5 ml procaine injections targeting painful joints for 10 consecutive days alternating between knee- and/or hip joints

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotherapy
Description: Kinesiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Description: Kinesiotherapy
Study: NCT06716476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Supplemental with Vitamin D 4000 IU
Study: NCT05971953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Energy Technique
Description: They would be receiving treatment as follow:~The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance( 75% of his and her available strength). After the relaxation, the muscle is lengthened more aggressively beyond the barrier and held for up to 15 seconds. Frequency: 10 reps for 4 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 20 mins

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional PT
Description: They would be receiving conventional treatment as follow:~including hot pack for 10 mins ischemic compression for 60 seconds .Frequency: 5 reps with 60 sec hold for 4 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins
Study: NCT05765487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil Cream, 3.6%

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle
Description: No Active or experimental ingredients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cream with only L-arginine
Study: NCT05631405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients treated with dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients treated with placebo